Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138838 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis
A Phase 3 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 55
- Enrollment target
NCT02138838 is a Phase 3 study that was terminated before completion, run by Amgen. The registered enrollment target is 55 participants.
The verdict
NCT02138838, a Phase 3 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 55 participants
- Enrollment target
Study Summary
The primary objective was to evaluate the efficacy of cinacalcet for reducing the plasma intact parathyroid hormone (iPTH) level by ≥ 30%.
Interventions
- DIETARY_SUPPLEMENT Standard of Care
- DRUG Cinacalcet HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2014-11-07 |
| Est. Completion | 2016-06-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02138838
The ClinicalTrials.gov registry entry for NCT02138838 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT02138838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02138838 about?
NCT02138838 is a clinical study titled "Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis". The primary objective was to evaluate the efficacy of cinacalcet for reducing the plasma intact parathyroid hormone (iPTH) level by ≥ 30%.
What is the current status of trial NCT02138838?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 2014-11-07. Estimated completion is 2016-06-23.
What interventions are being tested in trial NCT02138838?
The interventions under investigation include: Standard of Care (DIETARY_SUPPLEMENT), Cinacalcet HCl (DRUG).
Who is sponsoring clinical trial NCT02138838?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.